&

Jubilant, Janssen collaborate on neuroscience development

Thursday, June 30, 2011 01:28 PM

A Jubilant Life Sciences subsidiary has formed an alliance to deliver pre-clinical candidates in the neuroscience field to Belgium’s Janssen Pharmaceutica, according to PharmaTimes.

More... »

Gilead and J&J explore combo HIV Treatment

Wednesday, June 29, 2011 10:00 AM

Gilead and Johnson & Johnson's Tibotec subsidiary are joining forces on a combo HIV treatment, according to FierceBiotech. Under a new pact, Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. This new therapy follows a well-traveled development path as drug companies advance new HIV drugs that require fewer pills and offer greater potency.

More... »

Despite renewed growth in 2010, biotech industry faces R&D challenges

Tuesday, June 14, 2011 02:18 PM

The global biotechnology industry delivered solid top- and bottom-line growth in 2010, with the industry achieving aggregate profitability for the second year in a row.

More... »

Leukemia charity invests $3.7 million for trial network

Thursday, May 19, 2011 10:42 AM

Leukemia & Lymphoma Research, a U.K. charity, is investing $3.7 million in a national network of clinical trial centers to improve chances of survival for people suffering from leukaemia, lymphoma and myeloma.

More... »

EpiCept appoints new member to board of directors

Thursday, April 28, 2011 12:54 PM

EpiCept has appointed Keith L. Brownlie, former partner of Ernst & Young, to its board of directors.

More... »

Gore enrolls first patient in TIPS study for ascites

Tuesday, April 26, 2011 01:40 PM

W. L. Gore & Associates has enrolled the first patient in its Gore Early TIPS for Ascites Study. The patient was treated at Indiana University Hospital in Indianapolis, according to Fierce Medical Devices.

More... »

Vince & Associates Clinical Research expands

Thursday, April 21, 2011 12:33 PM

Kansas-based Vince & Associates Clinical Research, a provider of phase I-IV clinical trial services to the global biopharmaceutical industry, has opened a 90-bed clinical pharmacology research unit.

More... »

J&J looking to acquire Synthes

Tuesday, April 19, 2011 11:21 AM

Johnson & Johnson is looking to acquire global medical device manufacturer Synthes in a deal that could be worth around $20 billion as reported in Pharma Times.

More... »

Imperial acquisition of D. Anderson could signal consolidation trend in patient recruitment space

Monday, April 11, 2011 02:37 AM

Consolidation in the clinical trials industry is coming, many industry insiders say. It already has begun among drug sponsors and sporadically throughout the rest of the industry. But last week’s acquisition of D. Anderson & Co. by Imperial could mark the beginning of consolidation in the patient recruiting space.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »